Explore Our Biomarker Menu

Biological or Clinical Significance:

Soluble Fas (sFas) is generated by alternative mRNA splicing and lacks a transmembrane domain, is thought to inhibit Fas-FasL binding and blocks Fas-mediated apoptosis.

sFas has been identified in the supernatants of activated human lymphocytes and in several tumor cell lines, including hepatoma, osteosarcoma, and T- and B-cell leukemias and lymphomas. Elevated levels of sFas have also been observed in the serum of patients with solid tumors and hematopoietic malignancies. The clinical significance of serum sFas levels has not yet been clarified. The production of sFas may be involved in the pathogenesis of malignant disease.

References:

Analyte:

sFas

Matrix:

Status:

Experienced Running

Sensitivity-LLOQ:

Sensitivity-ULOQ:

platform

MSD-ECL

Required Sample Volume

Disease State:

MSD Panel:

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

    Immunogenicity

    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.